^
    Back
    Association details:
    Biomarker:MSI-H/dMMR
    Cancer:Esophageal Adenocarcinoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    08/29/2023
    Excerpt:
    Esophageal and Esophagogastric Junction Cancers: Adenocarcinoma…Preferred Regimens…MSI-H/dMMR tumors (independent of PD-L1 status)…Nivolumab and ipilimumab…
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Colorectal Cancer)
    New
    Title:

    FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer

    Excerpt:
    The Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for adult and pediatric patients 12 years of age and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-GI 2022
    Title:

    Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study.

    Published date:
    01/18/2022
    Excerpt:
    ...a total of 32 pts were enrolled (all had dMMR±MSI-H status; 16 with gastric cancer and 16 with OGA)….With a median follow-up of 10.9 months, 1 pt had metastatic relapse, 1 pt died without relapse and 30 pts were recurrence/progression-free....Neo-adjuvant therapy with nivolumab and ipilimumab is feasible and is associated with a high pCR rate in pts with MSI/dMMR resectable OGA.
    DOI:
    10.1200/JCO.2022.40.4_suppl.244